Preview
Full Doc
 | 2004 |
Press Release
Press Release (15K)
Doc #288331: Click preview link for longer preview.
FOR IMMEDIATE RELEASE
CURIS Reports Fourth Quarter and Fiscal 2003 Results
CAMBRIDGE, MA, February 5, 2004�Curis, Inc. (NASDAQ:CRIS), a therapeutic drug development company, today reported its financial results for the fourth quarter and fiscal year ended December 31, 2003.
For the fourth quarter of 2003, the Company reported a net loss applicable to common stockholders of $6,936,000, or ($0.17) per share as compared to net income of $12,070,000, or $0.35 per share for the prior year period.
Revenues for the fourth quarter of 2003 were . . .
288331
|
Wyeth
As referenced in this Press Release:
Wyeth – 10,900,000 from a private placement of our common stock in August. In January 2004, we entered into a collaboration agreement with Wyeth Pharmaceuticals in the field of neurological disorders, which we expect will become effective upon compliance with applicable anti-trust laws. During 2004, we
_____________
Wyeth; – Curis ability to enter into and maintain important strategic partnerships, including its ability to maintain its current collaboration agreements with Genentech, Ortho and Wyeth; the risk that competitors will discover and develop signaling pathway-based therapeutics faster and more successfully that Curis and its collaborators are
_____________
dt 227093
;
Curis
As referenced in this Press Release:
Curis, Inc. – dex991.htm PRESS RELEASE
Exhibit 99.1
FOR IMMEDIATE RELEASE
CURIS Reports Fourth Quarter and Fiscal 2003 Results
CAMBRIDGE, MA, February 5, 2004Curis, Inc. (NASDAQ:CRIS), a therapeutic drug development company, today reported its financial results for the fourth quarter and fiscal year ended December 31,
_____________
CURIS, INC – candidates, either through our corporate collaborations or as a result of our internal development efforts, will continue to advance towards human clinical testing.
CURIS, INC .
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
Three months ended
December 31,
Year ended
December 31,
2003
2002
2003
2002
Revenues
$
755,095
$
_____________
CURIS, INC – 40,426,650
35,528,208
36,015,610
32,267,106
1
See Computation of Diluted Earnings Per Share table attached herewith.
CURIS, INC .
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
December 31,
2003
December 31,
2002
ASSETS
Cash, cash equivalents, marketable securities and long-term investments
$
37,
_____________
CURIS, INC – 13,064,283
Total stockholders equity
38,865,213
19,736,042
Total liabilities and stockholders equity
$
55,736,490
$
62,441,693
###
CURIS, INC .
COMPUTATION OF DILUTED EARNINGS PER SHARE
(UNAUDITED)2
Three months
ended
December 31,
2002
Net income applicable to common stockholders, GAAP Basis
$
_____________
Curis, Inc – three months ended December 31, 2002 because the Company has incurred net losses applicable to common stockholders for all other periods presented.
About Curis, Inc .
Curis, Inc. is a therapeutic drug development company. The Companys technology focus is on regulatory pathways that control repair and regeneration. Curis
_____________
dt 239098
;
|
Elan
As referenced in this Press Release:
Elan Corp – the fact that in the fourth quarter of 2002 Curis received $1,299,000 in expense reimbursement related to its joint venture with Elan Corp oration, Curis Newco, which was subsequently terminated in May 2003. Further, during the fourth quarter of 2003, research and development expenses also included $
_____________
Elan Corp – Curis Hedgehog technology. The amendments reduced Curis future royalty payment obligations under these license agreements.
Because the Company entered into an agreement with Elan Corp oration to end its joint venture, Curis Newco, in May 2003, the Company did not record a loss relating to Curis Newco for
_____________
dt 236903
|
Preview
Full Doc
| 2004 |
For Immediate Release
For Immediate Release (12K)
Doc #289017: Click preview link for longer preview.
For more information:
Investor Relations
Media Relations
Jim DeNike
Colleen Beauregard
Corixa Corp.
Waggener Edstrom Bioscience
206.754.5716
503.443.7000
denike@corixa.com
colleenb@wagged.com
FOR IMMEDIATE RELEASE
CORIXA ANNOUNCES FOURTH QUARTER AND YEAR-END 2003 FINANCIAL RESULTS
Seattle, March 8, 2004 ? Corixa Corp. (Nasdaq: CRXA), a developer of immunotherapeutics, today announced financial results for the fourth quarter and year ended December 31, . . .
289017
|
Wyeth
As referenced in this For Immediate Release:
Wyeth. – recognized as a result of discontinuing development of PVAC in December 2003, as well as revenue from collaborative agreements with Zenyaku Kogyo and Wyeth. These increases were partially offset by the anticipated expiration of the funded research phase of our collaborative agreement with Zambon.
As of
_____________
dt 227095
;
Abbott Labs
As referenced in this For Immediate Release:
Abbott Laboratories. – funding by the NIH of our TLR4 agonist program, the initiation of a Phase I tuberculosis vaccine trial and our new collaboration with Abbott Laboratories.
Conference Call
Corixa will hold a conference call and webcast to discuss the fourth quarter and full year financial results Monday, March
_____________
dt 223414
;
|
Corixa
As referenced in this For Immediate Release:
Corixa Corp – EX-99.1 3 v97127exv99w1.htm EXHIBIT 99.1
Exhibit 99.1
For more information:
Investor Relations
Media Relations
Jim DeNike
Colleen Beauregard
Corixa Corp .
Waggener Edstrom Bioscience
206.754.5716
503.443.7000
denike@corixa.com
colleenb@wagged.com
FOR IMMEDIATE RELEASE
CORIXA ANNOUNCES FOURTH QUARTER
_____________
Corixa Corp – denike@corixa.com
colleenb@wagged.com
FOR IMMEDIATE RELEASE
CORIXA ANNOUNCES FOURTH QUARTER AND YEAR-END 2003 FINANCIAL RESULTS
Seattle, March 8, 2004 Corixa Corp . (Nasdaq: CRXA), a developer of immunotherapeutics, today announced financial results for the fourth quarter and year ended December 31, 2003.
For the
_____________
Corixa Corp – are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release.
# # #
-MORE-
Corixa Corp oration
Consolidated Statement of Operations
(In thousands except per share data)
Three months ended December 30,
Twelve months ended December 31,
2003
2002
_____________
dt 238514
|
Preview
Full Doc
| 2004 |
For Immediate Release
For Immediate Release (25K)
Doc #298452: Click preview link for longer preview.
04/CAT/05
Page 1 of 12
FOR IMMEDIATE RELEASE
07.00 GMT, 02:00 EST MONDAY 9 FEBRUARY 2004
For further information contact:
Cambridge Antibody Technology
Tel: +44 (0) 1223 471 471
Peter Chambr?, Chief Executive Officer
John Aston, Chief Financial Officer
Rowena Gardner, Director of Corporate Communications
Weber Shandwick Square Mile (Europe)
Tel: +44 (0) 20 7067 0700
Kevin Smith
Rachel Lankester
BMC Communications/The Trout Group (USA)
Tel: +1 212 477 9007
Brad Miles, ext 17 (media)
Brandon Lewis, ext 15 (investors)
CAMBRIDGE . . .
298452
|
Wyeth
As referenced in this For Immediate Release:
Wyeth – against the first royalty payment made by Abbott. Revenues of 0.6 million were generated from contract research fees under collaborations with Pfizer, Wyeth Research and Merck & Co., Inc. The research services being performed for Wyeth Research were completed during the period.
Direct costs for the three
_____________
Wyeth – million were generated from contract research fees under collaborations with Pfizer, Wyeth Research and Merck & Co., Inc. The research services being performed for Wyeth Research were completed during the period.
Direct costs for the three months ended 31 December 2003 were 0.2 million, reflecting royalties due
_____________
Wyeth – has also licensed its proprietary technologies to several companies. CAT's licensees include: Abbott, Amgen, Chugai, Human Genome Sciences, Merck & Co, Pfizer and Wyeth Research.
?
CAT is listed on the London Stock Exchange and on NASDAQ. CAT raised 41m in its IPO in March 1997 and 93m
_____________
dt 264721
;
Abbott Labs
As referenced in this For Immediate Release:
Abbott Laboratories – CAT and Genzyme, has been filed with the US Food and Drug Administration (FDA). Discussions with the FDA are ongoing.
HUMIRA
In January, Abbott Laboratories announced increased worldwide 2004 sales forecasts for HUMIRA (adalimumab), a human anti-TNFa monoclonal antibody and the first CAT-derived antibody to receive
_____________
dt 264524
;
CATG
As referenced in this For Immediate Release:
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP – Rachel Lankester
BMC Communications/The Trout Group (USA)
Tel: +1 212 477 9007
Brad Miles, ext 17 (media)
Brandon Lewis, ext 15 (investors)
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC
ANNOUNCES FIRST QUARTER FINANCIAL RESULTS
Cambridge, UK Cambridge Antibody Technology Group plc (LSE: CAT; NASDAQ: CATG) today announces financial results for the
_____________
Cambridge Antibody Technology Group – 9007
Brad Miles, ext 17 (media)
Brandon Lewis, ext 15 (investors)
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC
ANNOUNCES FIRST QUARTER FINANCIAL RESULTS
Cambridge, UK Cambridge Antibody Technology Group plc (LSE: CAT; NASDAQ: CATG) today announces financial results for the first quarter of its financial year, from 1 October 2003 to 31
_____________
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP – liquid resources at 31 December 2003 increased to 115.1 million from 107.8 million at 30 September 2003.
PAGE 6 of 12
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC
Preliminary Statement of Results for
the THREE MONTHS ended 31 DECEMBER 2003
CONSOLIDATED PROFIT AND LOSS ACCOUNT
(unaudited)
Three months
ended
31
_____________
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP – has been prepared in accordance with UK GAAP. The dollar translations are solely for the convenience of the reader.
PAGE 7 of 12
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC
Preliminary Statement of Results for
the THREE MONTHS ended 31 DECEMBER 2003
CONSOLIDATED BALANCE SHEET
(unaudited)
As at
31 December
2003
Convenience
_____________
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP – has been prepared in accordance with UK GAAP. The dollar translations are solely for the convenience of the reader.
PAGE 8 of 12
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC
PRELIMINARY STATEMENT OF RESULTS FOR
THE THREE MONTHS ENDED 31 DECEMBER 2003
CONSOLIDATED CASH FLOW STATEMENT
(unaudited)
Three months
ended
31 December
_____________
dt 264896
;
|
Genzyme
As referenced in this For Immediate Release:
Genzyme Corp – trial are expected in early 2005 when all patients will have completed at least one year of follow-up post surgery.
CAT and Genzyme Corp today announce preliminary results from a Phase I/II clinical trial of CAT-192, a human anti-TGFb1monoclonal antibody. The primary objective
_____________
dt 264475
;
Human Genome
As referenced in this For Immediate Release:
Human Genome Sciences, – LICENSED PRODUCT CANDIDATES
LymphoStat-B, a human monoclonal antibody which modulates the activities of B-lymphocytes, was isolated at CAT in collaboration with Human Genome Sciences, Inc (HGSI) and licensed to HGSI in 2001. In January 2004, HGSI announced that it has begun dosing patients in a Phase
_____________
Human Genome Sciences, – one at pre-clinical development stage.
?
CAT has also licensed its proprietary technologies to several companies. CAT's licensees include: Abbott, Amgen, Chugai, Human Genome Sciences, Merck & Co, Pfizer and Wyeth Research.
?
CAT is listed on the London Stock Exchange and on NASDAQ. CAT raised 41m in its
_____________
dt 262191
|
Preview
Full Doc
| 2003 |
For Immediate Release
For Immediate Release (49K)
Doc #298487: Click preview link for longer preview.
03/CAT/19
Page 1 of 15
FOR IMMEDIATE RELEASE
07.00 BST, 02.00 EST Wednesday 3 September 2003
For further information contact:
Cambridge Antibody Technology Weber Shandwick Square Mile (Europe)
----------------------------- ------------------------------------
Tel: +44 (0) 1223 471 471 Tel: +44 (0) 20 7067 0700
Peter Chambre, Chief Executive Officer Kevin Smith
John Aston, Chief Financial Officer Rachel Lankester
Rowena Gardner, Director of Corporate
Communications
. . .
298487
|
Wyeth
As referenced in this For Immediate Release:
Wyeth – clinical development stage at CAT's
collaborators.
Further discussions with respect to CAT's collaboration with Pfizer are
ongoing, as are discussions with Wyeth regarding the next phase of that
collaboration.
Today CAT announces that it has granted Xerion Pharmaceuticals AG, a private
German biotech company, options
_____________
Wyeth – approval of HUMIRA in Switzerland. Revenues of
(pound)3.2 million were generated from contract research fees under ongoing
collaborations with Pfizer, HGSI, Wyeth Research and Merck & Co., Inc of which
(pound)0.6 million was received during the third quarter. Licence fees of
(pound)1.7
_____________
Wyeth – has also licensed its proprietary technologies to several companies.
CAT's licensees include: Abbott, Amgen, Chugai, Human Genome Sciences,
Merck & Co, Pfizer and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT raised(pound)41m in its IPO
_____________
dt 264736
;
Abbott Labs
As referenced in this For Immediate Release:
Abbott
Laboratories. – adopted a
positive opinion on HUMIRA for the treatment of rheumatoid arthritis (RA).
HUMIRA was isolated and optimised by CAT in collaboration with Abbott
Laboratories. Abbott is responsible for the clinical development and marketing
of HUMIRA. HUMIRA is already marketed in the US and is the first
_____________
Abbott Laboratories) – of HUMIRA is governed by
an agreement dated 1 April 1995 between Cambridge Antibody Technology Limited
and Knoll Aktiengesellschaft (now a subsidiary of Abbott Laboratories) . The
agreement allows for offset, in certain circumstances, of royalties due to
third parties against royalties due to CAT, subject to a
_____________
dt 264529
;
CATG
As referenced in this For Immediate Release:
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP – Corporate
Communications
BMC Communications/The Trout Group (USA)
----------------------------------------
Tel: +1 212 477 9007
Brad Miles, ext 17 (media)
Brandon Lewis, ext 15 (investors)
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC ANNOUNCES FINANCIAL RESULTS FOR THE
NINE MONTHS ENDED 30 JUNE 2003
Cambridge, UK...Cambridge Antibody Technology Group plc (LSE: CAT; NASDAQ:
CATG)
_____________
.Cambridge Antibody Technology Group – Brandon Lewis, ext 15 (investors)
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC ANNOUNCES FINANCIAL RESULTS FOR THE
NINE MONTHS ENDED 30 JUNE 2003
Cambridge, UK...Cambridge Antibody Technology Group plc (LSE: CAT; NASDAQ:
CATG) today announces financial results for the nine months ended 30 June 2003
and an update on business since
_____________
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP – to the final costs associated with
the construction and fit out of CAT's premises at Granta Park.
{PAGE}
Page 7 of 15
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP plc
Results for the NINE MONTHS ended 30 June 2003
{TABLE}
{CAPTION}
CONSOLIDATED PROFIT AND LOSS ACCOUNT
(unaudited) Convenience Nine months Nine months
_____________
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP – been prepared in accordance with UK GAAP. The
dollar translations are solely for the convenience of the reader.
{PAGE}
Page 8 of 15
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP plc
Results for the NINE MONTHS ended 30 JUNE 2003
{TABLE}
{CAPTION}
CONSOLIDATED BALANCE SHEET
(unaudited) Convenience As at 30 June As at
_____________
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP – been prepared in accordance with UK GAAP. The
dollar translations are solely for the convenience of the reader.
{PAGE}
Page 9 of 15
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP plc
Results for the nine MONTHS ended 30 june 2003
{TABLE}
{CAPTION}
CONSOLIDATED CASH FLOW STATEMENT
(unaudited) Convenience Nine months Nine months Year
_____________
dt 264918
;
|
Human Genome
As referenced in this For Immediate Release:
Human Genome Sciences, – clinical development by the end of 2004.
Licensed Product Candidates
There has been progress with several antibodies deriving from CAT's
collaboration with Human Genome Sciences, Inc (HGSI): four are now in clinical
trials.
In April 2003, HGSI announced its intention to initiate Phase II clinical
trials of
_____________
Human Genome Sciences, – Amgen,
Amrad, Elan and Genzyme.
o CAT has also licensed its proprietary technologies to several companies.
CAT's licensees include: Abbott, Amgen, Chugai, Human Genome Sciences,
Merck & Co, Pfizer and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT
_____________
dt 262217
;
Merck
As referenced in this For Immediate Release:
Merck – in Switzerland. Revenues of
(pound)3.2 million were generated from contract research fees under ongoing
collaborations with Pfizer, HGSI, Wyeth Research and Merck & Co., Inc of which
(pound)0.6 million was received during the third quarter. Licence fees of
(pound)1.7 million were
_____________
Merck – and Genzyme.
o CAT has also licensed its proprietary technologies to several companies.
CAT's licensees include: Abbott, Amgen, Chugai, Human Genome Sciences,
Merck & Co, Pfizer and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT raised(
_____________
dt 261908
|
| Full Doc
| 2003 |
For Immediate Release
For Immediate Release (5K)
Doc #298492: This document is immediately available for purchase, but does not have a preview available for viewing.
298492
|
Wyeth
As referenced in this For Immediate Release:
Wyeth – for target validation and drug
discovery. CAT's collaborators include: Abbott, Amgen, Amrad, Chugai, Elan,
Genzyme, Human Genome Sciences, Merck & Co, Pfizer and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT raised(pound)41m in its IPO
_____________
dt 264738
;
CATG
As referenced in this For Immediate Release:
Cambridge Antibody Technology Group
– Genome Sciences, Inc.
Application of the Safe Harbor of the Private Securities Litigation Reform Act
of 1995:
This press release contains statements about Cambridge Antibody Technology Group
plc ("CAT") that are forward looking statements. All statements other than
statements of historical facts included in this press release may be
_____________
dt 264922
;
|
Human Genome
As referenced in this For Immediate Release:
HUMAN GENOME
SCIENCES, – Brandon Lewis, ext.15 (investors)
CAMBRIDGE ANTIBODY TECHNOLOGY REPORTS THE INITIATION OF CLINICAL
DEVELOPMENT OF TRAIL-R2 MAB FOR TREATMENT OF CANCER BY HUMAN GENOME
SCIENCES, INC
Cambridge, UK ... Cambridge Antibody Technology (LSE: CAT; NASDAQ: CATG) today
acknowledges the announcement by Human Genome Sciences, Inc (NASDAQ: HGSI) that
_____________
Human Genome Sciences, – FOR TREATMENT OF CANCER BY HUMAN GENOME
SCIENCES, INC
Cambridge, UK ... Cambridge Antibody Technology (LSE: CAT; NASDAQ: CATG) today
acknowledges the announcement by Human Genome Sciences, Inc (NASDAQ: HGSI) that
it has received clearance from the UK Medicines and Healthcare products
Regulatory Agency allowing it to begin clinical
_____________
Human Genome Sciences, – human phage
antibody libraries to several companies for target validation and drug
discovery. CAT's collaborators include: Abbott, Amgen, Amrad, Chugai, Elan,
Genzyme, Human Genome Sciences, Merck & Co, Pfizer and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT
_____________
Human Genome Sciences – 2001.
CAT raised(pound)41m in its IPO in March 1997 and(pound)93m
in a secondary offering in March 2000.
HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc.
Application of the Safe Harbor of the Private Securities Litigation Reform Act
of 1995:
This press
_____________
Human Genome Sciences, – its IPO in March 1997 and(pound)93m
in a secondary offering in March 2000.
HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc.
Application of the Safe Harbor of the Private Securities Litigation Reform Act
of 1995:
This press release contains statements about Cambridge
_____________
dt 262220
;
Merck
As referenced in this For Immediate Release:
Merck – libraries to several companies for target validation and drug
discovery. CAT's collaborators include: Abbott, Amgen, Amrad, Chugai, Elan,
Genzyme, Human Genome Sciences, Merck & Co, Pfizer and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT raised(
_____________
dt 261910
|
| Full Doc
| 2003 |
For Immediate Release
For Immediate Release (5K)
Doc #298493: This document is immediately available for purchase, but does not have a preview available for viewing.
298493
|
Wyeth
As referenced in this For Immediate Release:
Wyeth – for target validation and drug
discovery.
CAT's collaborators include: Abbott, Amgen, Amrad, Chugai, Elan,
Genzyme, Human Genome Sciences, Merck & Co, Pfizer and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT raised(pound)41m in its IPO
_____________
dt 264739
;
CATG
As referenced in this For Immediate Release:
Cambridge Antibody
Technology Group – selliing of Trabio
Application of the Safe Harbor of the Private Securities Litigation Reform Act
of 1995: This press release contains statements about Cambridge Antibody
Technology Group plc ("CAT") that are forward looking statements. All
statements other than statements of historical facts included in this press
release may be forward
_____________
dt 264923
;
|
Human Genome
As referenced in this For Immediate Release:
Human Genome Sciences, – phage
{PAGE}
antibody libraries to several companies for target validation and drug
discovery.
CAT's collaborators include: Abbott, Amgen, Amrad, Chugai, Elan,
Genzyme, Human Genome Sciences, Merck & Co, Pfizer and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT
_____________
dt 262221
;
Merck
As referenced in this For Immediate Release:
Merck – libraries to several companies for target validation and drug
discovery.
CAT's collaborators include: Abbott, Amgen, Amrad, Chugai, Elan,
Genzyme, Human Genome Sciences, Merck & Co, Pfizer and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT raised(
_____________
dt 261911
|
Preview
Full Doc
| 2003 | |
Wyeth
As referenced in this For Immediate Release:
Wyeth – for target validation and drug
discovery. CAT's collaborators include: Abbott, Amgen, Amrad, Chugai, Elan,
Genzyme, Human Genome Sciences, Merck & Co, Pfizer and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT raised(pound)41m in its IPO
_____________
dt 264740
;
Abbott Labs
As referenced in this For Immediate Release:
ABBOTT LABORATORIES – Group (USA)
----------------------------------------
Tel: 001 212 477 9007
Brad Miles, ext 17 (media)
Brandon Lewis, ext.15 (investors)
CAMBRIDGE ANTIBODY TECHNOLOGY REPORTS ANNOUNCEMENT
FROM ABBOTT LABORATORIES REGARDING HUMIRATM AND ABT-874
Cambridge, UK... Cambridge Antibody Technology (LSE: CAT; NASDAQ: CATG) today
acknowledges the announcement made by Abbott Laboratories at
_____________
Abbott Laboratories – FROM ABBOTT LABORATORIES REGARDING HUMIRATM AND ABT-874
Cambridge, UK... Cambridge Antibody Technology (LSE: CAT; NASDAQ: CATG) today
acknowledges the announcement made by Abbott Laboratories at a meeting held
yesterday for investors and financial analysts. Abbott announced that it has
raised its 2003 sales expectations for HUMIRATM from
_____________
Abbott Laboratories) – and Abbott, and was licensed by CAT to Abbott under the same
1995 agreement between CAT and Knoll Aktiengesellschaft (now a subsidiary of
Abbott Laboratories) . CAT receives development milestone payments and will
receive royalties on sales of ABT-874.
Notes to Editors
Cambridge Antibody Technology (CAT):
o
_____________
dt 264531
;
CATG
As referenced in this For Immediate Release:
Cambridge Antibody
Technology Group – in March 2000.
Application of the Safe Harbor of the Private Securities Litigation Reform Act
of 1995: This press release contains statements about Cambridge Antibody
Technology Group plc ("CAT") that are forward looking statements. All
statements other than statements of historical facts included in this press
release may be forward
_____________
dt 264924
;
|
Human Genome
As referenced in this For Immediate Release:
Human Genome Sciences, – human phage
antibody libraries to several companies for target validation and drug
discovery. CAT's collaborators include: Abbott, Amgen, Amrad, Chugai, Elan,
Genzyme, Human Genome Sciences, Merck & Co, Pfizer and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT
_____________
dt 262222
;
Merck
As referenced in this For Immediate Release:
Merck – libraries to several companies for target validation and drug
discovery. CAT's collaborators include: Abbott, Amgen, Amrad, Chugai, Elan,
Genzyme, Human Genome Sciences, Merck & Co, Pfizer and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT raised(
_____________
dt 261912
|
Preview
Full Doc
| 2003 |
For Immediate Release
For Immediate Release (51K)
Doc #298497: Click preview link for longer preview.
03/CAT/12
Page 1 of 12
FOR IMMEDIATE RELEASE
07.00 BST, 02.00 EST Monday 19 May 2003
For Further Information Contact:
Weber Shandwick Square Mile (Europe)
Cambridge Antibody Technology ------------------------------------
Tel: +44 (0) 1223 471 471 Tel: +44 (0) 20 7067 0700
Peter Chambre, Chief Executive Officer Kevin Smith
John Aston, Chief Financial Officer Graham Herring
Rowena Gardner, Director of Corporate
Communications BMC . . .
298497
|
Wyeth
As referenced in this For Immediate Release:
Wyeth – which
CAT carried out funded research for HGSI concluded in March 2003, when its
planned three year term expired. Discussions are underway with Wyeth regarding
the next phase of that collaboration.
Intellectual property
During December 2002 and January 2003 CAT successfully resolved all principal
patent litigation. Patent
_____________
Wyeth – of the current financial year. Revenues
of (pound)2.5 million were generated from contract research fees under ongoing
collaborations with Pfizer, HGSI, Wyeth Research and Merck & Co., Inc.
Technical milestone payments of (pound)0.2 million were received from Pfizer
during the first quarter of the
_____________
Wyeth – for target validation and
drug discovery. CAT's collaborators include: Abbott, Amgen, Amrad,
Chugai, Elan, Genzyme, Human Genome Sciences, Merck & Co, Pfizer and
Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT raised(pound)41m in its IPO
_____________
dt 264742
;
Abbott Labs
As referenced in this For Immediate Release:
Abbott Laboratories – our cash
position. We remain committed to building a strong, product-based, profitable
biopharmaceutical company."
Product development
Humira(TM)
On 31 December 2002, Abbott Laboratories announced that it had received US
Food and Drug Administration (FDA) approval to market Humira (adalimumab,
previously known as D2E7), a human anti-
_____________
Abbott Laboratories) – of Humira is governed by
an agreement dated 1 April 1995 between Cambridge Antibody Technology Limited
and Knoll Aktiengesellschaft (now a subsidiary of Abbott Laboratories) . The
agreement allows for offset, in certain circumstances, of royalties due to
third parties against royalties due to CAT, subject to a
_____________
dt 264533
;
CATG
As referenced in this For Immediate Release:
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP – cash burn for the year is now expected to
be less than (pound)40.0 million.
{PAGE}
{TABLE}
{CAPTION}
Page 6 of 12
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP plc
RESULTS FOR THE SIX MONTHS ENDED 31 MARCH 2003
CONSOLIDATED PROFIT AND LOSS ACCOUNT
(unaudited) Convenience Six months Six months Year ended
_____________
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP – prepared in accordance with UK GAAP. The
dollar translations are solely for the convenience of the reader.
{PAGE}
{CAPTION}
Page 7 of 12
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP plc
RESULTS FOR THE SIX MONTHS ENDED 31 MARCH 2003
CONSOLIDATED BALANCE SHEET
(unaudited) Convenience As at 31 As at 31 As at
_____________
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP – prepared in accordance with UK GAAP. The
dollar translations are solely for the convenience of the reader.
{PAGE}
{CAPTION}
Page 8 of 12
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP plc
RESULTS FOR THE SIX MONTHS ENDED 31 MARCH 2003
CONSOLIDATED CASH FLOW STATEMENT
(unaudited) Convenience Six months Six months Year ended
translation
_____________
Cambridge Antibody Technology Group – annual report and financial statements for the year ended 30 September
2002 are available from the Company's registered office:
The Company Secretary
Cambridge Antibody Technology Group plc
Milstein Building
Granta Park
Cambridge
CB1 6GH, UK
Tel: +44 (0) 1223 471471
{PAGE}
{TABLE}
{CAPTION}
Page 11 of 12
Quarterly financial
_____________
Cambridge Antibody Technology Group – in March 2000.
Application of the Safe Harbor of the Private Securities Litigation
Reform Act of 1995: This press release contains statements about
Cambridge Antibody Technology Group plc ("CAT") that are forward looking
statements. All statements other than statements of historical facts
included in this press release may be forward
_____________
dt 264926
;
|
Human Genome
As referenced in this For Immediate Release:
Human Genome Sciences, – allergic conjunctivitis, patient recruitment is
complete. Data are expected to be available in the third quarter of 2003.
Licensed Products
In April 2003, Human Genome Sciences, Inc (HGSI) announced the results of a
Phase I clinical trial of LymphoStat-B, a human anti-B-Lymphocyte Stimulator
(BLyS) antibody,
_____________
Human Genome Sciences, – human
phage antibody libraries to several companies for target validation and
drug discovery. CAT's collaborators include: Abbott, Amgen, Amrad,
Chugai, Elan, Genzyme, Human Genome Sciences, Merck & Co, Pfizer and
Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT
_____________
dt 262225
;
Merck
As referenced in this For Immediate Release:
Merck – were recognised in the
period, principally licence fees released from deferred income brought forward
at 30 September 2002. The library licence granted to Merck & Co., Inc. came
into effect during the second quarter of the current financial year. Revenues
of (pound)2.5 million were generated
_____________
Merck – financial year. Revenues
of (pound)2.5 million were generated from contract research fees under ongoing
collaborations with Pfizer, HGSI, Wyeth Research and Merck & Co., Inc.
Technical milestone payments of (pound)0.2 million were received from Pfizer
during the first quarter of the financial year.
_____________
Merck – libraries to several companies for target validation and
drug discovery. CAT's collaborators include: Abbott, Amgen, Amrad,
Chugai, Elan, Genzyme, Human Genome Sciences, Merck & Co, Pfizer and
Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT raised(
_____________
dt 261914
|
Preview
Full Doc
| 2003 |
For Immediate Release
For Immediate Release (4K)
Doc #298504: Click preview link for longer preview.
03/CAT/11
Page 1 of . . .
298504
|
Wyeth
As referenced in this For Immediate Release:
Wyeth – for target validation and drug
discovery. CAT's collaborators include: Abbott, Amgen, Amrad, Chugai, Elan,
Genzyme, Human Genome Sciences, Merck & Co, Pharmacia and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT raised(pound)41m in its IPO
_____________
dt 264743
;
Abbott Labs
As referenced in this For Immediate Release:
Abbott Laboratories – 9007
Brad Miles, ext 17 (media)
Brandon Lewis, ext.15 (investors)
CAMBRIDGE ANTIBODY TECHNOLOGY - HUMIRATM ROYALTIES
Cambridge, UK... As announced earlier this year, Abbott Laboratories received
FDA approval to market HumiraTM earlier than expected on 31 December 2002.
Humira was isolated and optimised by Cambridge Antibody Technology (LSE:
_____________
Abbott Laboratories) – of
Humira is governed by an agreement dated 1 April 1995 between Cambridge
Antibody Technology Limited and Knoll Aktiengesellschaft (now a subsidiary of
Abbott Laboratories) .
The agreement allows for offset, in certain circumstances, of royalties due to
third parties against royalties due to CAT, subject to a
_____________
dt 264534
;
CATG
As referenced in this For Immediate Release:
Cambridge Antibody Technology Group – in March 2000. Application of the Safe Harbor of
the Private Securities Litigation Reform Act of 1995: This press release
contains statements about Cambridge Antibody Technology Group plc ("CAT")
that are forward looking statements. All statements other than statements
of historical facts included in this press release may be forward
_____________
dt 264929
;
|
Human Genome
As referenced in this For Immediate Release:
Human Genome Sciences, – human phage
antibody libraries to several companies for target validation and drug
discovery. CAT's collaborators include: Abbott, Amgen, Amrad, Chugai, Elan,
Genzyme, Human Genome Sciences, Merck & Co, Pharmacia and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT
_____________
dt 262226
;
Merck
As referenced in this For Immediate Release:
Merck – libraries to several companies for target validation and drug
discovery. CAT's collaborators include: Abbott, Amgen, Amrad, Chugai, Elan,
Genzyme, Human Genome Sciences, Merck & Co, Pharmacia and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT raised(
_____________
dt 261915
|
| Full Doc
| 2003 |
For Immediate Release
For Immediate Release (5K)
Doc #298505: This document is immediately available for purchase, but does not have a preview available for viewing.
298505
|
Wyeth
As referenced in this For Immediate Release:
Wyeth – for target validation and
drug discovery. CAT's collaborators include: Abbott, Amgen, Amrad,
Chugai, Elan, Genzyme, Human Genome Sciences, Merck & Co, Pharmacia and
Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT raised (pound)41m in its IPO
_____________
dt 264744
;
CATG
As referenced in this For Immediate Release:
Cambridge Antibody Technology Group – in March 2000.
Application of the Safe Harbor of the Private Securities Litigation
Reform Act of 1995: This press release contains statements about
Cambridge Antibody Technology Group plc ("CAT") that are forward looking
statements. All statements other than statements of historical facts
included in this press release may be forward
_____________
dt 264930
;
|
Human Genome
As referenced in this For Immediate Release:
Human Genome Sciences, – Chambre, Chief Executive Officer ------------------------------------
John Aston, Chief Financial Officer Tel: +44 (0) 20 7067 0700
Rowena Gardner, Director of Corporate Graham Herring
Communications
Human Genome Sciences, Inc BMC Communications/The Trout Group (USA)
-------------------------- ----------------------------------------
Tel: 001 301 315 2777 Tel: 001 212 477 9007
Jerry Parrott, VP Corporate Brad
_____________
HUMAN GENOME SCIENCES, – Parrott, VP Corporate Brad Miles, ext 17 (media)
Communications Brandon Lewis, ext.15 (investors)
CAMBRIDGE ANTIBODY TECHNOLOGY REPORTS
THE DEVELOPMENT OF ABTHRAXTM
BY HUMAN GENOME SCIENCES, INC
Cambridge, UK... Cambridge Antibody Technology (LSE: CAT; NASDAQ: CATG) today
acknowledges the announcement by Human Genome Sciences, Inc. (NASDAQ: HGSI)
that
_____________
Human Genome Sciences, – THE DEVELOPMENT OF ABTHRAXTM
BY HUMAN GENOME SCIENCES, INC
Cambridge, UK... Cambridge Antibody Technology (LSE: CAT; NASDAQ: CATG) today
acknowledges the announcement by Human Genome Sciences, Inc. (NASDAQ: HGSI)
that it has discovered and developed a human monoclonal antibody drug,
ABthrax(TM), that is effective in protecting against
_____________
Human Genome Sciences, – human
phage antibody libraries to several companies for target validation and
drug discovery. CAT's collaborators include: Abbott, Amgen, Amrad,
Chugai, Elan, Genzyme, Human Genome Sciences, Merck & Co, Pharmacia and
Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT
_____________
dt 262227
;
Merck
As referenced in this For Immediate Release:
Merck – libraries to several companies for target validation and
drug discovery. CAT's collaborators include: Abbott, Amgen, Amrad,
Chugai, Elan, Genzyme, Human Genome Sciences, Merck & Co, Pharmacia and
Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT raised (
_____________
dt 261916
|
Preview
Full Doc
| 2003 | |
Wyeth
As referenced in this For Immediate Release:
Wyeth – for
target validation and drug discovery. CAT's collaborators include:
Abbott, Amgen, Amrad, Chugai, Elan, Genzyme, Human Genome Sciences,
Merck & Co, Pharmacia and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT raised(pound)41m in its IPO
_____________
dt 264745
;
CATG
As referenced in this For Immediate Release:
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP – Corporate Communications
BMC Communications/The Trout Group (USA)
----------------------------------------
Tel: +1 212 477 9007
Brad Miles, ext. 17 (media)
Brandon Lewis, ext. 15 (investors)
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC
ANNOUNCES RESULT OF EGM
Cambridge, UK...Cambridge Antibody Technology Group plc (LSE: CAT; NASDAQ:
CATG) announces that at its Extraordinary General Meeting,
_____________
.Cambridge Antibody Technology Group – 477 9007
Brad Miles, ext. 17 (media)
Brandon Lewis, ext. 15 (investors)
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC
ANNOUNCES RESULT OF EGM
Cambridge, UK...Cambridge Antibody Technology Group plc (LSE: CAT; NASDAQ:
CATG) announces that at its Extraordinary General Meeting, held earlier
today, all resolutions were duly passed with overwhelming support.
-
_____________
dt 264931
;
|
Human Genome
As referenced in this For Immediate Release:
Human Genome Sciences, – human phage antibody libraries to several companies for
target validation and drug discovery. CAT's collaborators include:
Abbott, Amgen, Amrad, Chugai, Elan, Genzyme, Human Genome Sciences,
Merck & Co, Pharmacia and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT
_____________
dt 262229
;
Merck
As referenced in this For Immediate Release:
Merck – libraries to several companies for
target validation and drug discovery. CAT's collaborators include:
Abbott, Amgen, Amrad, Chugai, Elan, Genzyme, Human Genome Sciences,
Merck & Co, Pharmacia and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT raised(
_____________
dt 261917
|
Preview
Full Doc
| 2003 |
For Immediate Release
For Immediate Release (36K)
Doc #298515: Click preview link for longer preview.
03/CAT/07
Page 1 of 12
FOR IMMEDIATE RELEASE
07.00 GMT 02.00 EST Thursday 13 February 2003
For Further Information Contact:
Cambridge Antibody Technology Weber Shandwick Square Mile (Europe)
Tel: +44 (0) 1223 471 471 Tel: +44 (0) 20 7067 0700
Peter Chambre, Chief Executive Officer Kevin Smith
John Aston, Chief Finanancial Officer Graham Herring
Rowena Gardner, Director of Corporate
Communications
BMC Communications/The Trout Group (USA)
. . .
298515
|
Wyeth
As referenced in this For Immediate Release:
Wyeth- – September 2002.
Revenues of (pound)0.6 million were generated from contract research fees
under ongoing collaborations with HGSI, Merck & Co., Inc. and Wyeth- Ayerst.
Operating costs for the period amounted to (pound)13.2 million (three
months ended 31 December 2001: (pound)7.7 million; year
_____________
Wyeth – for
target validation and drug discovery. CAT's collaborators include:
Abbott, Amgen, Amrad, Chugai, Elan, Genzyme, Human Genome Sciences,
Merck & Co, Pharmacia and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT raised (pound)41m in its IPO
_____________
dt 264746
;
Abbott Labs
As referenced in this For Immediate Release:
Abbott Laboratories – in the patents and
licensing area and, most recently, the announcement of the proposed merger
with Oxford GlycoSciences (OGS).
On 31 December 2002, Abbott Laboratories announced that it had received US
Food and Drug Administration (FDA) approval to market HumiraTM (adalimumab,
previously known as D2E7) for the treatment
_____________
dt 264535
;
CATG
As referenced in this For Immediate Release:
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP – Corporate
Communications
BMC Communications/The Trout Group (USA)
Tel: +1 212 477 9007
Brad Miles, ext. 17 (media)
Brandon Lewis, ext. 15 (investors)
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC
ANNOUNCES FIRST QUARTER RESULTS
Cambridge, UK...Cambridge Antibody Technology Group plc (LSE: CAT;
NASDAQ: CATG) today announces financial results for the first
_____________
.Cambridge Antibody Technology Group – 477 9007
Brad Miles, ext. 17 (media)
Brandon Lewis, ext. 15 (investors)
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC
ANNOUNCES FIRST QUARTER RESULTS
Cambridge, UK...Cambridge Antibody Technology Group plc (LSE: CAT;
NASDAQ: CATG) today announces financial results for the first
quarter of its 2003 financial year, from 1 October 2002 to
_____________
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP – final installment on the
Incyte Lifeseq(R) Gold database licence paid to Incyte in October 2002.
{PAGE}
Page 6 of 12
{TABLE}
{CAPTION}
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP plc
RESULTS FOR THE THREE MONTHS ENDED 31 DECEMBER 2002
CONSOLIDATED PROFIT AND LOSS ACCOUNT
(unaudited) Convenience Three months Three months Year ended
_____________
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP – prepared in accordance with UK GAAP.
The dollar translations are solely for the convenience of the reader.
{PAGE}
{CAPTION}
Page 7 of 12
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP plc
Results for the THREE MONTHS ended 31 DECEMBER 2002
Consolidated Balance Sheet
(unaudited) Convenience As at 31 As at 31 As at
_____________
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP – prepared in accordance with UK GAAP.
The dollar translations are solely for the convenience of the reader.
{PAGE}
Page 8 of 12
{CAPTION}
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP plc
Results for the THREE MONTHS ended 31 DECEMBER 2002
Consolidated Cash Flow Statement
(unaudited) Convenience Three months Three months Year ended 30
_____________
dt 264936
;
|
Human Genome
As referenced in this For Immediate Release:
Human Genome Sciences, – in allergic
conjunctivitis, patient recruitment is on schedule and nearly completed.
Data are expected to be available in the third quarter of 2003.
Human Genome Sciences, Inc. (HGSI), has reported that it has completed
patient enrolment in a Phase I clinical trial to evaluate LymphoStat-BTM
for use
_____________
Human Genome Sciences, – human phage antibody libraries to several companies for
target validation and drug discovery. CAT's collaborators include:
Abbott, Amgen, Amrad, Chugai, Elan, Genzyme, Human Genome Sciences,
Merck & Co, Pharmacia and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT
_____________
dt 262231
;
Merck
As referenced in this For Immediate Release:
Merck – brought forward at 30 September 2002.
Revenues of (pound)0.6 million were generated from contract research fees
under ongoing collaborations with HGSI, Merck & Co., Inc. and Wyeth-Ayerst.
Operating costs for the period amounted to (pound)13.2 million (three
months ended 31 December 2001: (
_____________
Merck – in recent periods.
{PAGE}
Page 5 of 12
Creditors increased during the period with the receipt of two up front
licence fees from Merck and Chugai.
During the period, the Group established a finance leasing facility under
which equipment with a cost of (pound)0.5 million
_____________
Merck – libraries to several companies for
target validation and drug discovery. CAT's collaborators include:
Abbott, Amgen, Amrad, Chugai, Elan, Genzyme, Human Genome Sciences,
Merck & Co, Pharmacia and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT raised (
_____________
dt 261918
|
Preview
Full Doc
| 2003 |
For Immediate Release
For Immediate Release (3K)
Doc #298516: Click preview link for longer preview.
02/CAT/06
Page 1 of . . .
298516
|
Wyeth
As referenced in this For Immediate Release:
Wyeth – discovery. CAT's collaborators include: Abbott, Amgen, Amrad, Chugai, Elan,
{PAGE}
Page 2 of 2
Genzyme, Human Genome Sciences, Merck & Co, Pharmacia and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT raised(pound)41m in its IPO
_____________
dt 264747
;
CATG
As referenced in this For Immediate Release:
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP – Corporate
Communications
BMC Communications/The Trout Group (USA)
Tel: +1 212 477 9007
Brad Miles, ext. 17 (media)
Brandon Lewis, ext. 15 (investors)
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC
REPORTS OUTCOME OF ANNUAL GENERAL MEETING
Cambridge, UK...Cambridge Antibody Technology (LSE: CAT, NASDAQ: CATG) reports
that at its Annual General Meeting,
_____________
dt 264937
;
|
Human Genome
As referenced in this For Immediate Release:
Human Genome Sciences, – several companies for target validation and drug
discovery. CAT's collaborators include: Abbott, Amgen, Amrad, Chugai, Elan,
{PAGE}
Page 2 of 2
Genzyme, Human Genome Sciences, Merck & Co, Pharmacia and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT
_____________
dt 262232
;
Merck
As referenced in this For Immediate Release:
Merck – target validation and drug
discovery. CAT's collaborators include: Abbott, Amgen, Amrad, Chugai, Elan,
{PAGE}
Page 2 of 2
Genzyme, Human Genome Sciences, Merck & Co, Pharmacia and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT raised(
_____________
dt 261919
|
Preview
Full Doc
| 2003 |
For Immediate Release
For Immediate Release (6K)
Doc #298520: Click preview link for longer preview.
03/CAT/03
Page 1 of 3
FOR IMMEDIATE RELEASE
10.30 GMT 05.30 EST 9 January 2002
For Further Information Contact:
Cambridge Antibody Technology Weber Shandwick Square Mile (Europe)
Tel: +44 (0) 1223 471 471 Tel: +44 (0) 20 7067 0700
Peter Chambre, Chief Executive Officer Kevin Smith
John Aston, Chief Financial Officer Graham Herring
Rowena Gardner, Director of Corporate
Communications
BMC Communications/The Trout Group (USA)
---------------------------------------- . . .
298520
|
Wyeth
As referenced in this For Immediate Release:
Wyeth – for
target validation and drug discovery. CAT's collaborators include:
Abbott, Amgen, Amrad, Chugai, Elan, Genzyme, Human Genome Sciences,
Merck & Co, Pharmacia and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since
June 2001. CAT raised(pound)41m in its IPO
_____________
dt 264749
;
CATG
As referenced in this For Immediate Release:
Cambridge Antibody
Technology Group – in March 2000.
Application of the Safe Harbor of the Private Securities Litigation Reform Act
of 1995: This press release contains statements about Cambridge Antibody
Technology Group plc ("CAT") that are forward looking statements. All statements
other than statements of historical facts included in this press release may be
forward
_____________
dt 264940
;
Human Genome
As referenced in this For Immediate Release:
Human Genome Sciences, – human phage antibody libraries to several companies for
target validation and drug discovery. CAT's collaborators include:
Abbott, Amgen, Amrad, Chugai, Elan, Genzyme, Human Genome Sciences,
Merck & Co, Pharmacia and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since
June 2001. CAT
_____________
dt 262234
;
|
Merck
As referenced in this For Immediate Release:
Merck – libraries to several companies for
target validation and drug discovery. CAT's collaborators include:
Abbott, Amgen, Amrad, Chugai, Elan, Genzyme, Human Genome Sciences,
Merck & Co, Pharmacia and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since
June 2001. CAT raised(
_____________
dt 261922
;
Pfizer
As referenced in this For Immediate Release:
Pfizer Inc – 2002.
{PAGE}
Page 2 of 3
Prior to joining Bristol-Myers Squibb Company in 1997 he held a number of
senior posts at Pfizer Inc , most recently Senior Vice President Worldwide Drug
Discovery and European Medicinal R&D. He joined Pfizer UK in 1982. Previously,
Peter held
_____________
Pfizer Inc – of Biochemistry
Department (1976 - 1978), Chairman of Anti-inflammatory projects
(1978 - 1979);
o 1979 -1982 Sandoz Research Institute: Division Director;
o 1982 -1996 Pfizer Inc : Senior Vice President European Medicinal
Research and Development (1992-1996), Senior Vice President
and Worldwide Head of Drug Discovery (1992-1996);
o
_____________
dt 264640
|
Preview
Full Doc
| 2003 |
Cambridge Antibody Technology and Dyax Expand Licensing Agreement
Cambridge Antibody Technology and Dyax Expand Licensing Agreement (9K)
Doc #298521: Click preview link for longer preview.
FOR IMMEDIATE RELEASE
07.00 GMT 02.00 EST, 6 January 2003
For further information contact:
Cambridge Antibody Technology Weber Shandwick Square Mile (Europe)
Tel: +44 (0) 1223 471 471 Tel: +44 (0) 20 7067 0700
Peter Chambre, Chief Executive Officer Kevin Smith
John Aston, Chief Financial Officer Graham Herring
Rowena Gardner, Director of Corporate
Communications
Dyax Corp BMC Communications/The Trout Group (USA)
--------- ----------------------------------------
Jack Morgan, Senior Vice President, Tel: 001 212 477 9007
Corporate Development & Business Brad Miles, ext 17 (media)
Operations Brandon Lewis, ext. 15 (investors)
Tel: 001 617 250 5762
Sondra Henrichon, Director Investor
Relations and Corporate Communications
Tel: 001 617 250 5839
CAMBRIDGE ANTIBODY TECHNOLOGY AND DYAX EXPAND LICENSING AGREEMENT
Cambridge, UK and Cambridge, MA...Cambridge Antibody Technology (LSE: CAT;
NASDAQ:CATG) and Dyax Corp. (NASDAQ: DYAX) today announce an agreement to
expand access and freedom to operate under each other's phage display patents.
This agreement expands upon those reached in 1997 under which Dyax licensed
its Ladner phage display patents to CAT and CAT granted certain limited rights
to Dyax under antibody phage display patents controlled by CAT. Under the
terms of this expanded agreement, CAT is granting Dyax worldwide licences for
research and certain other purposes under all the antibody phage display
patents controlled by CAT. Dyax will also receive options for licences to
298521
|
Wyeth
As referenced in this Cambridge Antibody Technology and Dyax Expand Licensing Agreement:
Wyeth – for
target validation and drug discovery. CAT's collaborators include:
Abbott, Amgen, Amrad, Chugai, Elan, Genzyme, Human Genome Sciences,
Merck & Co, Pharmacia and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since
June 2001. CAT raised(pound)41m in its IPO
_____________
dt 264750
;
CATG
As referenced in this Cambridge Antibody Technology and Dyax Expand Licensing Agreement:
Cambridge Antibody
Technology Group – 2000.
For CAT
Application of the Safe Harbor of the Private Securities Litigation Reform
Act of 1995: This press release contains statements about Cambridge Antibody
Technology Group plc ("CAT") that are forward looking statements. All
statements other than statements of historical facts included in this press
release may be forward
_____________
dt 264941
;
Dyax
As referenced in this Cambridge Antibody Technology and Dyax Expand Licensing Agreement:
Dyax Corp – 20 7067 0700
Peter Chambre, Chief Executive Officer Kevin Smith
John Aston, Chief Financial Officer Graham Herring
Rowena Gardner, Director of Corporate
Communications
Dyax Corp BMC Communications/The Trout Group (USA)
--------- ----------------------------------------
Jack Morgan, Senior Vice President, Tel: 001 212 477 9007
Corporate Development & Business Brad Miles, ext
_____________
Dyax Corp – 250 5839
CAMBRIDGE ANTIBODY TECHNOLOGY AND DYAX EXPAND LICENSING AGREEMENT
Cambridge, UK and Cambridge, MA...Cambridge Antibody Technology (LSE: CAT;
NASDAQ:CATG) and Dyax Corp . (NASDAQ: DYAX) today announce an agreement to
expand access and freedom to operate under each other's phage display patents.
This agreement
_____________
Dyax Corp – antibody patent portfolio; it is the third patent licensing
agreement we have executed in the last month."
Jack Morgan, Senior Vice President of Dyax Corp ., commented: "We believe this
agreement will expand pharmaceutical and biotechnology companies' access to
state-of-the-art technology and ultimately benefit patients
_____________
Dyax Corp – market conditions, CAT's ability to enter into and
maintain collaborative arrangements, success of product candidates in
clinical trials, regulatory developments and competition.
Dyax Corp
o Dyax Corp. is a biopharmaceutical company focused on the discovery,
development and commercialization of therapeutic products. The Company
uses its patented
_____________
Dyax Corp – s ability to enter into and
maintain collaborative arrangements, success of product candidates in
clinical trials, regulatory developments and competition.
Dyax Corp
o Dyax Corp . is a biopharmaceutical company focused on the discovery,
development and commercialization of therapeutic products. The Company
uses its patented phage display technology
_____________
dt 264169
;
|
Human Genome
As referenced in this Cambridge Antibody Technology and Dyax Expand Licensing Agreement:
Human Genome Sciences, – human phage antibody libraries to several companies for
target validation and drug discovery. CAT's collaborators include:
Abbott, Amgen, Amrad, Chugai, Elan, Genzyme, Human Genome Sciences,
Merck & Co, Pharmacia and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since
June 2001. CAT
_____________
dt 262235
;
Merck
As referenced in this Cambridge Antibody Technology and Dyax Expand Licensing Agreement:
Merck – libraries to several companies for
target validation and drug discovery. CAT's collaborators include:
Abbott, Amgen, Amrad, Chugai, Elan, Genzyme, Human Genome Sciences,
Merck & Co, Pharmacia and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since
June 2001. CAT raised(
_____________
dt 261923
|
Preview
Full Doc
| 2002 |
For Immediate Release
For Immediate Release (8K)
Doc #298523: Click preview link for longer preview.
EXHBIT 99.1
02/CAT/28
FOR IMMEDIATE RELEASE
07.00 GMT 02.00 EST 23 December 2002
For further information contact:
Cambridge Antibody Technology Weber Shandwick Square Mile (Europe)
Tel: +44 (0) 1223 471 471 Tel: +44 (0) 20 7950 2800
Peter Chambre, Chief Executive Officer Kevin Smith
John Aston, Chief Financial Officer Graham Herring
Rowena Gardner, Director of Corporate
Communications
MorphoSys BMC Communications/The Trout Group (USA)
------- . . .
298523
|
Wyeth
As referenced in this For Immediate Release:
Wyeth – for target validation and drug
discovery. CAT's collaborators include: Abbott, Amgen, Amrad, Chugai, Elan,
Genzyme, Human Genome Sciences, Merck & Co, Pharmacia and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT raised(pound)41m in its IPO
_____________
dt 264751
;
Biogen
As referenced in this For Immediate Release:
Biogen Inc – is used by researchers
worldwide for human antibody generation.
o The Company currently has licensing and research collaborations with Bayer
(Berkeley, California/USA), Biogen Inc . (Cambridge, Massachusetts/USA),
Bristol-Myers Squibb (Wilmington, Delaware/USA), Centocor Inc. (Malvern,
Pennsylvania/USA), GPC Biotech AG (Munich/Germany), Hoffmann-La Roche
_____________
dt 276535
;
CATG
As referenced in this For Immediate Release:
Cambridge Antibody Technology Group – patents.
For CAT
Application of the Safe Harbor of the Private Securities Litigation
Reform Act of 1995: This press release contains statements about
Cambridge Antibody Technology Group plc ("CAT") that are forward looking
statements. All statements other than statements of historical facts
included in this press release may be forward
_____________
dt 264942
;
|
Human Genome
As referenced in this For Immediate Release:
Human Genome Sciences, – human phage
antibody libraries to several companies for target validation and drug
discovery. CAT's collaborators include: Abbott, Amgen, Amrad, Chugai, Elan,
Genzyme, Human Genome Sciences, Merck & Co, Pharmacia and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001.
CAT
_____________
dt 262236
;
ImmunoGen
As referenced in this For Immediate Release:
ImmunoGen – USA),
Bristol-Myers Squibb (Wilmington, Delaware/USA), Centocor Inc. (Malvern,
Pennsylvania/USA), GPC Biotech AG (Munich/Germany), Hoffmann-La Roche AG
(Basel/Switzerland), ImmunoGen Inc. (Cambridge, Massachusetts/USA), Oridis
Biomed GmbH (Graz/Austria), ProChon Biotech Ltd. (Rehovot/Israel), Schering
AG (Berlin/Germany) and Xoma Ltd. (Berkeley, California/
_____________
dt 259854
;
More... |
Preview
Full Doc
| 2002 |
For Immediate Release
For Immediate Release (8K)
Doc #298524: Click preview link for longer preview.
EXHIBIT 99.2
02/CAT/29
FOR IMMEDIATE RELEASE
07.00 GMT 02.00 EST 23 December 2002
For further information contact:
Cambridge Antibody Technology Weber Shandwick Square Mile (Europe)
Tel: +44 (0) 1223 471 471 Tel: +44 (0) 20 7067 0700
Peter Chambre, Chief Executive Officer Kevin Smith
John Aston, Chief Financial Officer Graham Herring
Rowena Gardner, Director of Corporate
Communications
XOMA BMC Communications/The Trout Group (USA)
----- . . .
298524
|
Wyeth
As referenced in this For Immediate Release:
Wyeth – for target validation and drug
discovery. CAT's collaborators include: Abbott, Amgen, Amrad, Chugai, Elan,
Genzyme, Human Genome Sciences, Merck & Co, Pharmacia and Wyeth Research.
o Based near Cambridge, England, CAT currently employs around 290 people.
o CAT is listed on the London Stock Exchange and on
_____________
dt 264752
;
CATG
As referenced in this For Immediate Release:
Cambridge Antibody Technology Group – in March 2000.
Application of the Safe Harbor of the Private Securities Litigation
Reform Act of 1995: This press release contains statements about
Cambridge Antibody Technology Group plc ("CAT") that are forward looking
statements. All statements other than statements of historical facts
included in this press release may be forward
_____________
dt 264943
;
Genentech
As referenced in this For Immediate Release:
Genentech, Inc – and manufacturers innovative biopharmaceuticals for
disease targets that include cancer, immunological and inflammatory
disorders, and infectious diseases. XOMA's programs include
collaborations: with Genentech, Inc . on the Raptiva(TM) antibody for
psoriasis (Phase III), rheumatoid arthritis (Phase II) and other
indications; with Onyx Pharmaceuticals, Inc. to develop
_____________
dt 259938
;
|
Human Genome
As referenced in this For Immediate Release:
Human Genome Sciences, – human phage
antibody libraries to several companies for target validation and drug
discovery. CAT's collaborators include: Abbott, Amgen, Amrad, Chugai, Elan,
Genzyme, Human Genome Sciences, Merck & Co, Pharmacia and Wyeth Research.
o Based near Cambridge, England, CAT currently employs around 290 people.
o CAT is listed on
_____________
dt 262237
;
Merck
As referenced in this For Immediate Release:
Merck – libraries to several companies for target validation and drug
discovery. CAT's collaborators include: Abbott, Amgen, Amrad, Chugai, Elan,
Genzyme, Human Genome Sciences, Merck & Co, Pharmacia and Wyeth Research.
o Based near Cambridge, England, CAT currently employs around 290 people.
o CAT is listed on the
_____________
dt 261925
;
More... |
Preview
Full Doc
| 2002 |
For Immediate Release
For Immediate Release (7K)
Doc #298525: Click preview link for longer preview.
02/CAT/27
Page 1 of 3
FOR IMMEDIATE RELEASE
07.00 GMT 02.00 EST 20 December 2002
For further information contact:
Cambridge Antibody Technology Weber Shandwick Square Mile (Europe)
Tel: +44 (0) 1223 471 471 Tel: +44 (0) 20 7067 0700
Peter Chambre, Chief Executive Officer Kevin Smith
John Aston, Chief Financial Officer Graham Herring
Rowena Gardner, Director of Corporate
Communications
Crucell NV BMC Communications/The Trout Group
Arie Bos, Director Corporate (USA)
Communications: . . .
298525
|
Wyeth
As referenced in this For Immediate Release:
Wyeth – for
target validation and drug discovery. CAT's collaborators include:
Abbott, Amgen, Amrad, Chugai, Elan, Genzyme, Human Genome Sciences,
Merck & Co, Pharmacia and Wyeth Research.
o Based near Cambridge, England, CAT currently employs around 290 people.
o CAT is listed on the London Stock Exchange and on
_____________
dt 264753
;
CATG
As referenced in this For Immediate Release:
Cambridge Antibody
Technology Group – 3 of 3
Application of the Safe Harbor of the Private Securities Litigation
Reform Act of 1995:
This press release contains statements about Cambridge Antibody
Technology Group plc ("CAT") that are forward looking statements. All
statements other than statements of historical facts included in this
press release may be forward
_____________
dt 264944
;
Crucell
As referenced in this For Immediate Release:
Crucell NV – 20 7067 0700
Peter Chambre, Chief Executive Officer Kevin Smith
John Aston, Chief Financial Officer Graham Herring
Rowena Gardner, Director of Corporate
Communications
Crucell NV BMC Communications/The Trout Group
Arie Bos, Director Corporate (USA)
Communications: Tel: 001 212 477 9007
Tel. +31-(0)71-524 8722;
_____________
Crucell N.V. – com
CAMBRIDGE ANTIBODY TECHNOLOGY AND CRUCELL
SETTLE PATENT DISPUTE
Cambridge, UK and Leiden, The Netherlands... Cambridge Antibody Technology
(LSE: CAT; NASDAQ: CATG) and Crucell N.V. (Euronext, NASDAQ: CRXL) announce
today that they have agreed on terms whereby Crucell receives from CAT a
worldwide licence with respect to
_____________
Crucell N.V. – CAT's ability to enter into and maintain collaborative arrangements,
success of product candidates in clinical trials, regulatory
developments and competition.
Crucell
o Crucell N.V. discovers and develops biopharmaceuticals that use the
human immune system to combat cancer, infectious diseases and other
conditions. Crucell leverages its patented technologies,
_____________
dt 265350
;
|
Human Genome
As referenced in this For Immediate Release:
Human Genome Sciences, – human phage antibody libraries to several companies for
target validation and drug discovery. CAT's collaborators include:
Abbott, Amgen, Amrad, Chugai, Elan, Genzyme, Human Genome Sciences,
Merck & Co, Pharmacia and Wyeth Research.
o Based near Cambridge, England, CAT currently employs around 290 people.
o CAT is listed on
_____________
dt 262238
;
J&J
As referenced in this For Immediate Release:
Johnson & Johnson – product
pipeline. Partners include Merck & Co. for the HIV vaccine, the
National Institutes of Health (NIH) for the Ebola vaccine and
Centocor, a Johnson & Johnson company, for the CD46 antibody for
treatment of various types of cancer. In addition, Crucell has over 20
licensees for its PER.C6(
_____________
dt 262302
;
More... |
Preview
Full Doc
| 2002 |
For Immediate Release
For Immediate Release (69K)
Doc #298535: Click preview link for longer preview.
02/CAT/26
Page 1 of 22
FOR IMMEDIATE RELEASE
07.00 GMT 02.00 EST 18 NOVEMBER 2002
For further information contact:
Cambridge Antibody Technology Weber Shandwick Square Mile (Europe)
Tel: +44 (0) 1763 263 233 Tel: +44 (0) 20 7950 2800
Peter Chambre, Chief Executive Officer Kevin Smith
John Aston, Chief Financial Officer Graham Herring
Rowena Gardner, Director of Corporate
Communications
BMC Communications/The Trout Group
( . . .
298535
|
Wyeth
As referenced in this For Immediate Release:
Wyeth – I/II results for CAT-213
o TRAIL-R1 mAb IND filed and approved (HGSI)
o Five exclusive therapeutic licences granted (HGSI, Amgen, Wyeth Research)
o Research alliance signed with Chugai
o Second agreement with Merck & Co., Inc. (since year end)
o Royalty obligations to DRC bought
_____________
Wyeth – pre- clinical/clinical development and marketing of
the product candidates.
J695, a human anti-IL-12 monoclonal antibody being developed by Abbott and
Wyeth Research continues to be tested in multi-centre Phase II clinical
trials as a potential treatment for RA and Crohn's disease.
LymphoStat-
_____________
Wyeth – derived human
monoclonal antibody candidate directed to a cell-surface receptor
protein rather than a soluble cytokine.
o In June 2002 CAT granted Wyeth Research an exclusive product licence
to a human antibody identified by CAT against a disease target
supplied by Wyeth.
o In October 2002,
_____________
Wyeth. – June 2002 CAT granted Wyeth Research an exclusive product licence
to a human antibody identified by CAT against a disease target
supplied by Wyeth.
o In October 2002, CAT granted HGSI an option for an exclusive licence
to an antibody to an undisclosed target, the fourth
_____________
Wyeth – one further antibody in the final quarter of the
financial year. In addition, licences for undisclosed targets have been
granted to Amgen and Wyeth Research. During the 2001 financial year one
non-recurring licence fee was received pursuant to collaborative
arrangements with HGSI. Revenues derived from these
_____________
dt 264755
;
AstraZeneca
As referenced in this For Immediate Release:
AstraZeneca PLC, – Director. Ake has extensive senior management experience,
covering finance and the pharmaceutical industry, and most recently held
the post of Executive Director at AstraZeneca PLC, with responsibility for
business development, incorporating corporate strategy and mergers &
acquisitions. Previously, he was Chief Financial Officer at Astra AB. Ake
takes
_____________
dt 258933
;
CATG
As referenced in this For Immediate Release:
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP – Corporate
Communications
BMC Communications/The Trout Group
(USA)
Tel: 001 212 477 9007
Brad Miles, ext.17 (media)
Brandon Lewis, ext.15 (investors)
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP plc
PRELIMINARY STATEMENT OF RESULTS
FOR THE YEAR ENDED 30 SEPTEMBER 2002
Highlights
o Significant pipeline progress
o HumiraTM filed for approval (Abbott)
_____________
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP – for products already in
human clinical trials and through the acquisition and in-licensing of other
new products."
{PAGE}
Page 3 of 22
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP plc PRELIMINARY
STATEMENT OF RESULTS FOR THE YEAR ENDED 30 SEPTEMBER 2002
Chairman's Statement
With significant progress in a number of areas,
_____________
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP – to the increase in
operating costs as described above offset by lower levels of capital
expenditure.
{PAGE}
Page 15 of 22
{TABLE}
{CAPTION}
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP plc
Preliminary Statement of Results for the Year ended 30 September 2002
CONSOLIDATED PROFIT AND LOSS ACCOUNT
Convenience Year ended Year ended Year
_____________
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP – prepared in accordance with UK GAAP.
The dollar translations are solely for the convenience of the reader.
{PAGE}
Page 16 of 22
{CAPTION}
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP plc
Preliminary Statement of Results for the Year ended 30 September 2002
Consolidated Balance Sheet
Convenience As at 30 As at 30
translation
_____________
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP – prepared in accordance with UK GAAP.
The dollar translations are solely for the convenience of the reader.
{PAGE}
Page 17 of 22
{CAPTION}
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP plc
Preliminary Statement of Results for the Year ended 30 September 2002
Consolidated Cash Flow Statement
Convenience Year ended 30 Year ended Year
_____________
dt 264948
;
|
Human Genome
As referenced in this For Immediate Release:
Human Genome Sciences, – potential treatment for RA and Crohn's disease.
LymphoStat-B(TM), a human monoclonal antibody against B-Lymphocyte
Stimulator (BLyS) being developed by Human Genome Sciences, Inc. (HGSI)
entered a Phase I clinical trial to determine its safety and pharmacology
in patients with systemic lupus erythematosus (SLE).
{PAGE}
_____________
Human Genome Sciences, – human phage antibody libraries to several companies for
target validation and drug discovery. CAT's collaborators include:
Abbott, Amgen, Amrad, Chugai, Elan, Genzyme, Human Genome Sciences,
Merck & Co, Pharmacia and Wyeth Research.
o CAT is listed on the London Stock Exchange and on NASDAQ since
June 2001. CAT
_____________
dt 262241
;
Merck
As referenced in this For Immediate Release:
Merck – and approved (HGSI)
o Five exclusive therapeutic licences granted (HGSI, Amgen, Wyeth Research)
o Research alliance signed with Chugai
o Second agreement with Merck & Co., Inc. (since year end)
o Royalty obligations to DRC bought back
o Net Cash Outflow:(pound)28.3m
o Cash & liquid
_____________
Merck – the
application of its technologies for the creation of antibody therapeutic
candidates.
o October 2001 CAT entered a collaboration and licence agreement with
Merck & Co., Inc. for the research and development of products
specific for a key target involved in disease mediated by HIV.
o December
_____________
Merck – license CAT's libraries for
discovery and development of potential human antibody therapeutics.
o October 2002 CAT entered into a second agreement with Merck & Co.,
Inc, granting Merck a licence to CAT's libraries. The libraries will
be used by Merck to support and promote discovery
_____________
Merck – for
discovery and development of potential human antibody therapeutics.
o October 2002 CAT entered into a second agreement with Merck & Co.,
Inc, granting Merck a licence to CAT's libraries. The libraries will
be used by Merck to support and promote discovery research and
development across a
_____________
Merck – entered into a second agreement with Merck & Co.,
Inc, granting Merck a licence to CAT's libraries. The libraries will
be used by Merck to support and promote discovery research and
development across a broad range of therapeutic areas.
In order to secure CAT's human monoclonal
_____________
dt 261928
|
Preview
Full Doc
| 2002 |
For Immediate Release
For Immediate Release (6K)
Doc #298543: Click preview link for longer preview.
02/CAT/22
Page 1 of 3
FOR IMMEDIATE RELEASE
08.00 BST, 03.00 EST Tuesday 13 August 2002
For Further Information Contact:
Cambridge Antibody Technology Weber Shandwick Square Mile (Europe)
Tel: +44 (0) 1763 263 233 Tel: +44 (0) 20 7950 2800
Peter Chambre, Chief Executive Officer Kevin Smith
John Aston, Chief Financial Officer Graham Herring
Rowena Gardner, Director of Corporate
Communications
BMC Communications/The Trout Group (USA) Xerion Pharmaceuticals
------------------------ . . .
298543
|
Wyeth
As referenced in this For Immediate Release:
Wyeth- – companies for
target validation and drug discovery. CAT's collaborators include:
Abbott , Amrad, Elan, Genzyme, Human Genome Sciences, Immunex, Merck &
Co, Pharmacia and Wyeth- Ayerst.
{PAGE}
Page 3 of 3
o CAT is listed on the London Stock Exchange and on NASDAQ since June
2001. CAT raised (
_____________
dt 264758
;
CATG
As referenced in this For Immediate Release:
Cambridge Antibody Technology Group – several research institutes.
Application of the Safe Harbor of the Private Securities
Litigation Reform Act of 1995: This press release contains statements about
Cambridge Antibody Technology Group plc ("CAT") that are forward looking
statements. All statements other than statements of historical facts
included in this press release may be forward
_____________
dt 264951
;
|
Human Genome
As referenced in this For Immediate Release:
Human Genome Sciences, – its
proprietary human phage antibody libraries to several companies for
target validation and drug discovery. CAT's collaborators include:
Abbott , Amrad, Elan, Genzyme, Human Genome Sciences, Immunex, Merck &
Co, Pharmacia and Wyeth-Ayerst.
{PAGE}
Page 3 of 3
o CAT is listed on the London Stock Exchange and
_____________
dt 262246
;
Merck
As referenced in this For Immediate Release:
Merck – antibody libraries to several companies for
target validation and drug discovery. CAT's collaborators include:
Abbott , Amrad, Elan, Genzyme, Human Genome Sciences, Immunex, Merck &
Co, Pharmacia and Wyeth-Ayerst.
{PAGE}
Page 3 of 3
o CAT is listed on the London Stock Exchange and on NASDAQ
_____________
dt 261931
|